University of Minnesota. Driven to Discover.
Students have more than triple the risk of contracting serogroup B meningococcal disease.
A survey of primary care docs reveals significant gaps in their knowledge of serogroup B meningococcal vaccines.
Though coverage still isn't optimal, for the first time rates topped 60%, with the boys' level gaining ground on the girls'.
The cluster has been classified as a meningococcal C outbreak, but a cofactor may be involved.
In the wake of new laws and tighter federal oversight, the FDA has done more than 400 inspections, sent 150 warning letters, and overseen 125 recalls.
Liberian official says meningitis is the possible cause of puzzling cases.
Most recipients produced antibodies, but 34% had no immune response to the outbreak strain.
Vaccination campaigns have nearly eliminated serogroup A meningitis cases from Africa.
The vaccine against a strain that affects only Africa has been a resounding success.
ACIP stops short of recommending routine use of group B vaccine in young people.
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2019 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.